Epidermal growth factor receptor mutations in lung cancer (Q29615474)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

1 reference

Sharma SV

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

Bell DW

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

Settleman J

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

Haber DA

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

March 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

published in

Nature Reviews Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

30 April 2017

page(s)

169-81

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

The new World Health Organization classification of lung tumours

30 April 2017

cites work

1 reference

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

31 March 2020

1 reference

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

31 March 2020

1 reference

Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?

31 March 2020

1 reference

Where next for gefitinib in patients with lung cancer?

31 March 2020

1 reference

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

31 March 2020

1 reference

EGFR and cancer prognosis

31 March 2020

1 reference

Epidermal growth factor receptors in non-small cell lung cancer

31 March 2020

1 reference

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

31 March 2020

1 reference

Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer

31 March 2020

1 reference

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

31 March 2020

1 reference

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

Epidermal growth factor receptor mutation testing in the care of lung cancer patients

31 March 2020

1 reference

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

31 March 2020

1 reference

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

31 March 2020

1 reference

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

31 March 2020

1 reference

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

31 March 2020

1 reference

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

31 March 2020

1 reference

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

31 March 2020

1 reference

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

31 March 2020

1 reference

Erlotinib in lung cancer - molecular and clinical predictors of outcome

31 March 2020

1 reference

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

31 March 2020

1 reference

A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma

31 March 2020

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

31 March 2020

1 reference

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

31 March 2020

1 reference

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R

31 March 2020

1 reference

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

31 March 2020

1 reference

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

31 March 2020

1 reference

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

31 March 2020

1 reference

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

31 March 2020

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

31 March 2020

1 reference

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

31 March 2020

1 reference

Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications

31 March 2020

1 reference

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

31 March 2020

1 reference

The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line

31 March 2020

1 reference

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

31 March 2020

1 reference

A small molecule-kinase interaction map for clinical kinase inhibitors

31 March 2020

1 reference

EGFR mutation in gefitinib-responsive small-cell lung cancer

31 March 2020

1 reference

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

31 March 2020

1 reference

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

31 March 2020

1 reference

Somatic mutations of EGFR in colorectal cancers and glioblastomas

31 March 2020

1 reference

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

31 March 2020

1 reference

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

31 March 2020

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

31 March 2020

1 reference

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

31 March 2020

1 reference

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

31 March 2020

1 reference

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

31 March 2020

1 reference

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

31 March 2020

1 reference

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

31 March 2020

1 reference

Predictors of the response to gefitinib in refractory non-small cell lung cancer

31 March 2020

1 reference

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

31 March 2020

1 reference

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer

31 March 2020

1 reference

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

31 March 2020

1 reference

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

31 March 2020

1 reference

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

31 March 2020

1 reference

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

31 March 2020

1 reference

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer

31 March 2020

1 reference

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

31 March 2020

1 reference

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

31 March 2020

1 reference

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

31 March 2020

1 reference

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

31 March 2020

1 reference

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

31 March 2020

1 reference

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

31 March 2020

1 reference

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

31 March 2020

1 reference

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer

31 March 2020

1 reference

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

31 March 2020

1 reference

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

31 March 2020

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

31 March 2020

1 reference

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

31 March 2020

1 reference

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

31 March 2020

1 reference

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

31 March 2020

1 reference

Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis

31 March 2020

1 reference

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

31 March 2020

1 reference

A matter of life and cell death

31 March 2020

1 reference

Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras.

31 March 2020

1 reference

Regulation of both apoptosis and cell survival by the v-Src oncoprotein.

31 March 2020

1 reference

v-Src generates a p53-independent apoptotic signal

31 March 2020

1 reference

Regulation of cell death by the Abl tyrosine kinase

31 March 2020

1 reference

Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis

31 March 2020

1 reference

Induction of apoptosis in fibroblasts by c-myc protein

31 March 2020

1 reference

Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas

31 March 2020

1 reference

Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung

31 March 2020

1 reference

K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos

31 March 2020

1 reference

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

31 March 2020

1 reference

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

31 March 2020

1 reference

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

31 March 2020

1 reference

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

31 March 2020

1 reference

Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers

31 March 2020

1 reference

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

31 March 2020

1 reference

Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines

31 March 2020

1 reference

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

31 March 2020

1 reference

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib

31 March 2020

1 reference

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

31 March 2020

1 reference

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

31 March 2020

1 reference

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

31 March 2020

1 reference

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

31 March 2020

1 reference

Strategies to overcome resistance to targeted protein kinase inhibitors

31 March 2020

1 reference

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

31 March 2020

1 reference

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.

31 March 2020

1 reference

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

31 March 2020

1 reference

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

31 March 2020

1 reference

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

31 March 2020

1 reference

BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

31 March 2020

1 reference

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

31 March 2020

1 reference

Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein

31 March 2020

1 reference

Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases

31 March 2020

1 reference

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

31 March 2020

1 reference

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

31 March 2020

1 reference

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

31 March 2020

1 reference

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors

31 March 2020

1 reference

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

31 March 2020

1 reference

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

31 March 2020

1 reference

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

31 March 2020

1 reference

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

31 March 2020

1 reference

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

31 March 2020

1 reference

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

31 March 2020

1 reference

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors

31 March 2020

1 reference

Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

31 March 2020

1 reference

Gefitinib--a novel targeted approach to treating cancer

31 March 2020

1 reference

Ras, PI(3)K and mTOR signalling controls tumour cell growth

31 March 2020

1 reference

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

31 March 2020

1 reference

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

31 March 2020

1 reference

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

31 March 2020

1 reference

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

31 March 2020

1 reference

Therapeutic potential of target of rapamycin inhibitors

31 March 2020

1 reference

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

31 March 2020

1 reference

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

31 March 2020

1 reference

The Akt-mTOR tango and its relevance to cancer

31 March 2020

1 reference

Novel combinations based on epidermal growth factor receptor inhibition

31 March 2020

1 reference

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

31 March 2020

1 reference

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

31 March 2020

1 reference

Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.

31 March 2020

1 reference

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

31 March 2020

1 reference

Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer

31 March 2020

1 reference

Lung cancer: intragenic ERBB2 kinase mutations in tumours

31 March 2020

1 reference

The consensus coding sequences of human breast and colorectal cancers

31 March 2020

1 reference

A loss-of-function RNA interference screen for molecular targets in cancer

31 March 2020

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

31 March 2020

1 reference

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

31 March 2020

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

Essential role for oncogenic Ras in tumour maintenance

31 March 2020

1 reference

Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes

31 March 2020

1 reference

Reversible tumorigenesis by MYC in hematopoietic lineages

31 March 2020

1 reference

Cancer revoked: oncogenes as therapeutic targets

31 March 2020

1 reference

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

31 March 2020

1 reference

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

31 March 2020

1 reference

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

31 March 2020

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

31 March 2020

1 reference

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

31 March 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

31 March 2020

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1032628685

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=17318210

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017